Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia

被引：0
|
作者：
Swaminathan, Mahesh
Przespolewski, Amanda
Griffiths, Elizabeth A.
Thompson, James E.
Elshoury, Amro
Walinski, Wendy
Wang, Eunice S.
机构：
[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[2] Roswell Pk Comprehens Canc Ctr, Dept Med, Leukemia Serv, Buffalo, NY USA
[3] Roswell Pk Comprehens Canc Ctr, Clin Res Serv, Buffalo, NY USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152947
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4426
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Randomized trial of GM-CSF and G-CSF following high-dose cytarabine and mitoxantrone chemotherapy for relapsed and refractory acute leukemia.
    Baer, Maria R.
    Ford, Laurie A.
    Bundy, Brian N.
    Tighe, Sheila M.
    O'Loughlin, Kieran L.
    Slack, James L.
    Wetzler, Meir
    Wallace, Paul K.
    [J]. BLOOD, 2006, 108 (11) : 223B - 223B
  • [42] A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia
    DeAngelo, Daniel J.
    Brunner, Andrew M.
    Werner, Lillian
    Avigan, David
    Fathi, Amir T.
    Sperling, Adam S.
    Washington, Abigail
    Stroopinsky, Dina
    Rosenblatt, Jacalyn
    McMasters, Malgorzata
    Luptakova, Katarina
    Wadleigh, Martha
    Steensma, David P.
    Hobbs, Gabriela S.
    Attar, Eyal C.
    Amrein, Philip C.
    Ebert, Benjamin L.
    Stone, Richard M.
    Ballen, Karen K.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (02) : 254 - 261
  • [43] A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Christian, Sonia
    Patel, Pritesh
    Agrawal, Vaibhav
    Griffin, Shawn
    Cahill, Kirk
    Khan, Irum
    Sweiss, Karen
    Shergill, Ardaman
    Calip, Gregory Sampang
    Stock, Wendy
    Odenike, Olatoyosi
    Konig, Heiko
    Quigley, John G.
    [J]. BLOOD, 2018, 132
  • [44] High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
    Stone, Richard M.
    Moser, Barry
    Sanford, Ben
    Schulman, Philip
    Kolitz, Jonathan E.
    Allen, Steven
    Stock, Wendy
    Galinsky, Ilene
    Vij, Ravi
    Marcucci, Guido
    Hurd, David
    Larson, Richard A.
    [J]. LEUKEMIA RESEARCH, 2011, 35 (03) : 329 - 333
  • [45] Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms
    Kopmar, Noam E.
    Gooley, Ted
    Curley, Niall
    Russell, Kathryn
    Shaw, Carole
    Schonhoff, Kelda
    Lim, John
    Halpern, Anna B.
    Walter, Roland B.
    Scott, Bart L.
    Appelbaum, Jacob
    Hendrie, Paul C.
    Estey, Elihu H.
    Percival, Mary-Elizabeth M.
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 (05) : 1057 - 1059
  • [46] Clofarabine and Low-Dose Cytarabine Combination in Relapsed/Refractory Acute Myeloid Leukemia Patients with High Risk Features
    Vigil, Carlos
    Jahan, Nusrat
    Paun, Oana
    Weis, Jennifer
    Heckman, Kevin
    Silverman, Margarida
    Carter, Thomas
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S297 - S297
  • [47] Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results
    Klisovic, Rebecca B.
    Wang, Hongyan
    Walker, Alison
    Walsh, Katherine
    Vasu, Sumithira
    Garzon, Ramiro
    Devine, Steven M.
    Wang, Jiang
    Garr, Celia
    Norris, Adam
    Byrd, John C.
    Grever, Michael R.
    Blum, William
    Chan, Kenneth K.
    Marcucci, Guido
    [J]. BLOOD, 2012, 120 (21)
  • [48] A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
    Saygin, Caner
    Larkin, Karilyn
    Blachly, James S.
    Orwick, Shelley
    Ngankeu, Apollinaire
    Gregory, Charles T.
    Phelps, Mitch A.
    Mani, Shylaja
    Walker, Alison
    Garzon, Ramiro
    Vasu, Sumithira
    Walsh, Katherine J.
    Bhatnagar, Bhavana
    Klisovic, Rebecca B.
    Grever, Michael R.
    Marcucci, Guido
    Byrd, John C.
    Blum, William
    Mims, Alice S.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : 1457 - 1465
  • [49] Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia
    Deisseroth, Albert
    Farrell, Ann
    Justice, Robert
    Kane, Robert
    Sridhara, Rajeshwari
    Chen, Huanyu
    He, Kun
    Pazdur, Richard
    [J]. BLOOD, 2010, 115 (02) : 430 - 430
  • [50] A phase I study of idarubicin dose escalation with amifostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes
    Garcia-Manero, G
    Faderl, S
    Giles, F
    Thomas, D
    Cortes, J
    O'Brien, S
    Davis, J
    Kantarjian, HM
    Estey, E
    [J]. HAEMATOLOGICA, 2002, 87 (08) : 804 - 807
12345